|
||||||||||||||||||||||||||
| SEC Info℠ | | | Home | | | Search | | | My Interests | | | Help | | | Sign In | | | Please Sign In | |||||||
|
||||||||||||||||||||||||||
As Of Filer Filing For·On·As Docs:Size Issuer Filing Agent 9/15/20 Cell MedX Corp. 10-K 5/31/20 84:2.9M Empire Stock Transf… Inc |
Document/Exhibit Description Pages Size
1: 10-K Annual Report HTML 495K
2: EX-10.68 Loan Agreement and Note Payable Dated April 13, HTML 28K
2020, Among Cell Medx Corp. and Longview
Investment Limited
3: EX-10.69 Loan Agreement Dated July 3, 2020, Among Cell Medx HTML 30K
Corp. and David Jeffs
4: EX-10.70 Loan Agreement and Note Payable Dated August 31, HTML 28K
2020, Among Cell Medx Corp. and Tradex Capital
Corp.
5: EX-21.1 List of Subsidiaries HTML 23K
6: EX-31.1 Certification -- §302 - SOA'02 HTML 27K
7: EX-31.2 Certification -- §302 - SOA'02 HTML 27K
8: EX-32.1 Certification -- §906 - SOA'02 HTML 24K
9: EX-32.2 Certification -- §906 - SOA'02 HTML 24K
16: R1 Document and Entity Information HTML 79K
17: R2 Consolidated Balance Sheets HTML 92K
18: R3 Consolidated Balance Sheets - Parenthetical HTML 30K
19: R4 Consolidated Statements of Operations HTML 86K
20: R5 Consolidated Statement of Stockholders' Deficit HTML 71K
21: R6 Consolidated Statements of Cash Flows HTML 97K
22: R7 Organization and Nature of Operations HTML 28K
23: R8 Summary of Significant Accounting Policies HTML 39K
24: R9 Related Party Transactions Disclosure HTML 38K
25: R10 Inventory Disclosure HTML 27K
26: R11 Other Current Assets Disclosure HTML 26K
27: R12 Equipment Disclosure HTML 31K
28: R13 Unearned Revenue Disclosure HTML 40K
29: R14 Revenue Disclosure HTML 29K
30: R15 Notes and Advances Payable Disclosure HTML 46K
31: R16 Share Capital Disclosure HTML 46K
32: R17 Income Taxes Disclosure HTML 39K
33: R18 Subsequent Event Disclosure HTML 27K
34: R19 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basis HTML 26K
of Presentation (Policies)
35: R20 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Principles of Consolidation, Policy (Policies)
36: R21 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 29K
Accounting Estimates, Policy (Policies)
37: R22 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 28K
Foreign Currency Translations and Transactions,
Policy (Policies)
38: R23 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Revenue Recognition, Policy (Policies)
39: R24 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 28K
Inventory Valuation, Policy (Policies)
40: R25 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Research and Development Costs, Policy (Policies)
41: R26 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Income HTML 30K
Taxes, Policy (Policies)
42: R27 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Loss HTML 27K
Per Share, Policy (Policies)
43: R28 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 28K
Long-lived Assets, Policy (Policies)
44: R29 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: HTML 27K
Equipment, Policy (Policies)
45: R30 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Fair HTML 28K
Value Measurements, Policy (Policies)
46: R31 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Stock HTML 28K
Options and Other Stock-based Compensation, Policy
(Policies)
47: R32 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Recent HTML 27K
Accounting Pronouncements (Policies)
48: R33 Related Party Transactions Disclosure: Schedule of HTML 31K
Amounts Due to Related Parties (Tables)
49: R34 Related Party Transactions Disclosure: Schedule of HTML 30K
Transactions with Related Parties (Tables)
50: R35 Equipment Disclosure: Change in book value of the HTML 30K
equipment (Tables)
51: R36 Unearned Revenue Disclosure: Changes to Unearned HTML 32K
Revenue (Tables)
52: R37 Unearned Revenue Disclosure: Schedule of Loss on HTML 28K
Reacquisition of Distribution Rights (Tables)
53: R38 Revenue Disclosure: Schedule of Revenue and HTML 28K
Associated Costs (Tables)
54: R39 Notes and Advances Payable Disclosure: Schedule of HTML 38K
Short-term Loans and Advances Outstanding (Tables)
55: R40 Share Capital Disclosure: Schedule of Stock Option HTML 31K
Activity (Tables)
56: R41 Share Capital Disclosure: Schedule of Stock HTML 29K
Options Outstanding (Tables)
57: R42 Share Capital Disclosure: Schedule of Warrant HTML 28K
Activity (Tables)
58: R43 Share Capital Disclosure: Schedule of Warrant HTML 31K
Details (Tables)
59: R44 Income Taxes Disclosure: Schedule of Effective HTML 32K
Income Tax Rate Reconciliation (Tables)
60: R45 Income Taxes Disclosure: Schedule of Deferred Tax HTML 30K
Assets and Liabilities (Tables)
61: R46 Organization and Nature of Operations (Details) HTML 27K
62: R47 Related Party Transactions Disclosure: Schedule of HTML 36K
Amounts Due to Related Parties (Details)
63: R48 Related Party Transactions Disclosure: Schedule of HTML 34K
Transactions with Related Parties (Details)
64: R49 Inventory Disclosure (Details) HTML 36K
65: R50 Other Current Assets Disclosure (Details) HTML 28K
66: R51 Equipment Disclosure: Change in book value of the HTML 33K
equipment (Details)
67: R52 Unearned Revenue Disclosure: Changes to Unearned HTML 38K
Revenue (Details)
68: R53 Unearned Revenue Disclosure (Details) HTML 37K
69: R54 Unearned Revenue Disclosure: Schedule of Loss on HTML 31K
Reacquisition of Distribution Rights (Details)
70: R55 Revenue Disclosure: Schedule of Revenue and HTML 41K
Associated Costs (Details)
71: R56 Notes and Advances Payable Disclosure: Schedule of HTML 46K
Short-term Loans and Advances Outstanding
(Details)
72: R57 Notes and Advances Payable Disclosure (Details) HTML 41K
73: R58 Share Capital Disclosure (Details) HTML 61K
74: R59 Share Capital Disclosure: Schedule of Stock Option HTML 32K
Activity (Details)
75: R60 Share Capital Disclosure: Schedule of Stock HTML 34K
Options Outstanding (Details)
76: R61 Share Capital Disclosure: Schedule of Warrant HTML 30K
Activity (Details)
77: R62 Share Capital Disclosure: Schedule of Warrant HTML 41K
Details (Details)
78: R63 Income Taxes Disclosure: Schedule of Effective HTML 45K
Income Tax Rate Reconciliation (Details)
79: R64 Income Taxes Disclosure: Schedule of Deferred Tax HTML 32K
Assets and Liabilities (Details)
80: R65 Income Taxes Disclosure (Details) HTML 28K
81: R66 Subsequent Event Disclosure (Details) HTML 32K
83: XML IDEA XML File -- Filing Summary XML 151K
82: EXCEL IDEA Workbook of Financial Reports XLSX 75K
10: EX-101.INS XBRL Instance -- cmxc-20200531 XML 637K
12: EX-101.CAL XBRL Calculations -- cmxc-20200531_cal XML 74K
13: EX-101.DEF XBRL Definitions -- cmxc-20200531_def XML 309K
14: EX-101.LAB XBRL Labels -- cmxc-20200531_lab XML 543K
15: EX-101.PRE XBRL Presentations -- cmxc-20200531_pre XML 505K
11: EX-101.SCH XBRL Schema -- cmxc-20200531 XSD 149K
84: ZIP XBRL Zipped Folder -- 0001393905-20-000276-xbrl Zip 69K
| ex-10.69 |
LOAN AGREEMENT
THIS LOAN AGREEMENT (this "Agreement") dated this 3rd day of July, 2020
BETWEEN:
David M. Jeffs of 2615 15th Avenue West, Vancouver, BC V6K 2Z6, Canada
(the "Lender")
OF THE FIRST PART
AND
Cell MedX Corp. of 123 W. Nye Lane, Suite 446, Carson City, NV 89706, USA
(the "Borrower")
OF THE SECOND PART
IN CONSIDERATION OF the Lender loaning certain monies (the "Loan") to the Borrower, and the Borrower repaying the Loan to the Lender, both parties agree to keep, perform and fulfill the promises and conditions set out in this Agreement:
Loan Amount & Interest
The Lender promises to loan twenty thousand ($20,000.00) CAD, to the Borrower and the Borrower promises to repay this principal amount to the Lender, at such address as may be provided in writing, with interest calculated and compounded monthly on the unpaid principal at the rate of 6.0% per annum.
Payment
This Loan will be repaid in full from the first proceeds the Borrower receives through the exercise of any existing warrants currently outstanding for the purchase of the Borrower’s common shares or One (1) year from the execution of this Agreement, whichever event arrives soonest.
At any time while not in default under this Agreement, the Borrower may pay the outstanding balance then owing under this Agreement to the Lender without further bonus or penalty.
Default
Notwithstanding anything to the contrary in this Agreement, if the Borrower defaults in the performance of any obligation under this Agreement, then the Lender may declare the principal amount owing and interest due under this Agreement at that time to be immediately due and payable.
Governing Law
This Agreement will be construed in accordance with and governed by the laws of the Province of British Columbia.
Costs
All costs, expenses and expenditures including, without limitation, the complete legal costs incurred by enforcing this Agreement as a result of any default by the Borrower, will be added to the principal then outstanding and will immediately be paid by the Borrower.
Binding Effect
This Agreement will pass to the benefit of and be binding upon the respective heirs, executors, administrators, successors and permitted assigns of the Borrower and Lender. The Borrower waives presentment for payment, notice of non-payment, protest, and notice of protest.
Amendments
This Agreement may only be amended or modified by a written instrument executed by both the Borrower and the Lender.
Severability
The clauses and paragraphs contained in this Agreement are intended to be read and construed independently of each other. If any term, covenant, condition or provision of this Agreement is held by a court of competent jurisdiction to be invalid, void or unenforceable, it is the parties' intent that such provision be reduced in scope by the court only to the extent deemed necessary by that court to render the provision reasonable and enforceable and the remainder of the provisions of this Agreement will in no way be affected, impaired or invalidated as a result.
General Provisions
Headings are inserted for the convenience of the parties only and are not to be considered when interpreting this Agreement. Words in the singular mean and include the plural and vice versa. Words in the masculine mean and include the feminine and vice versa.
Entire Agreement
This Agreement constitutes the entire agreement between the parties and there are no further items or provisions, either oral or otherwise.
IN WITNESS WHEREOF, the parties have duly affixed their signatures under hand and seal on this 3rd day of July, 2020.
| SIGNED, SEALED, AND DELIVERED this 9th day of July, 2020 in front of the person below who is over 18 years of age.
_/s/ Heidi Henderson (signature of witness)
WITNESS DETAILS: Name:
Address: _______________
Vancouver, BC
|
|
/s/ David Jeffs David M. Jeffs
|
| SIGNED, SEALED, AND DELIVERED this 9th day of July, 2020 in front of the person below who is over 18 years of age.
/s/ Greg Ball (signature of witness)
WITNESS DETAILS: Name:
Address: _______________
Vancouver, BC
|
|
Cell MedX Corp.
per: /s/ Joao da Costa Joao (John) da Costa
|